Galderma lifted its full-year 2026 sales guidance following record first-half net sales of $3.134 billion, a material beat that reflects accelerating demand across its injectable and device portfolios. The Swiss aesthetics-focused company's H1 performance was driven by strong uptake of Botox, Juvéderm, and Sculptra, alongside growing contribution from its energy-device business.
Business & M&A
Galderma Raises 2026 Guidance After $3.1B H1 Sales
Record first-half performance triggers full-year outlook boost, signaling sustained momentum in aesthetics.
Record $3.1B H1 sales trigger full-year guidance raise.
The guidance raise signals confidence in sustained market tailwinds—particularly the GLP-1 weight-loss phenomenon, which has expanded demand for preventive neuromodulator treatments and filler correction of temporal hollowing. For practice owners, the implication is clear: major manufacturers are investing aggressively in supply, rebate programs, and market development. Galderma's integrated model (toxin + filler + devices) continues to outperform pure-play competitors, reinforcing the strategic value of a diversified treatment menu.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.